Wahls Elimination Diet Reduces Fatigue and Improves Quality of Life for MS Patients
The Wahls elimination diet had more significant effects on quality of life for individuals with relapsing-remitting multiple sclerosis as compared to the Swank diet.
Relapsing Remitting Multiple Sclerosis
Natalizumab More Effective Than Fingolimod, BRACETD in RES RRMS
Natalizumab was more effective than fingolimod or BRACETD in reducing relapses in rapidly evolving severe relapsing-remitting multiple sclerosis.
Suicidal Ideation and Depression in Patients with MS
Risks for suicidal ideation and depressive symptoms are not different between patients with progressive and relapsing-remitting multiple sclerosis.
Bafiertam Now Available for Relapsing Forms of Multiple Sclerosis
Bafiertam is a novel fumarate bioequivalent alternative to its prodrug dimethyl fumarate.
Ocrelizumab Not Associated With Increased Severity of SARS-CoV-2 in MS
In patients with both multiple sclerosis and SARS-CoV-2 infection, treatment with ocrelizumab was not associated with increased infection severity.
Relapse Rates Lower With Ofatumumab in Multiple Sclerosis
Annualized relapse rates are lower for patients with relapsing MS receiving anti-CD20 monoclonal antibody ofatumumab compared with teriflunomide.
Relapses Linked to Accelerated Disability Progression in SPMS
For patients with secondary progressive multiple sclerosis, relapses are associated with accelerated disability progression.
Greater Proportion of RMS Patients Achieve NEDA-3 With Ofatumumab vs Teriflunomide
Treatment with ofatumumab was associated with a greater proportion of patients with relapsing forms of multiple sclerosis achieving no evidence of disease activity, compared with those who received teriflunomide.
Monomethyl Fumarate Gets Final FDA Approval for Multiple Sclerosis
The FDA has granted final approval to Bafiertam™ (monomethyl fumarate; Banner Life Sciences) for the treatment of relapsing forms of multiple sclerosis.
Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis
The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
-
Loading...
-
Loading...
Next post in Multiple Sclerosis
